Alfred Kingsley

Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel.

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.

Part of Atlas Capital Partners Ltd., LifeMap Sciences, Inc. is a company that provides stem cell information services. The company is based in Alameda, CA. The CEO of the company is Yaron Guan-Golan. LifeMap Sciences was acquired by Atlas Capital Partners Ltd. from AgeX Therapeutics, Inc. on March 15, 2021 for $0.50 million.

Ascendance Biotechnology, Inc. engages in the sale of cell-based assay products. It offers Hepregen and ESI Bio. The firm also offers stem cell technology. The company was founded by Vincent R. Zurawski, Jr. and Jeffrey D. Janus is headquartered in Alameda, CA.

AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.